Brickell Biotech (NASDAQ: BBI – Get Rating) released its quarterly earnings results Thursday. The company reported ($ 0.08) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($ 0.06) for ($ 0.02), MarketWatch earnings reports. Brickell Biotech had a negative return on equity of 163.84% and a negative net margin of 9,770.79%. During the same period last year, the company earned ($ 0.15) earnings per share.
Shares of the NASDAQ BBI opened Friday at $ 0.19. Brickell Biotech has a twelve-month low of $ 0.19 and a twelve-month high of $ 1.04. The stock has a 50-day simple moving average of $ 0.26 and a 200-day simple moving average of $ 0.27.
Several equity analysts recently commented on the company. Lake Street Capital downgraded Brickell Biotech from a “buy” rating to a “hold” rating in a research report on Friday. William Blair began coverage on Brickell Biotech in a research report on Tuesday, March 8. They have established an “outperform” rating on the stock. HC Wainwright began coverage on Brickell Biotech in a research report on Tuesday, Jan.18. They issued a “buy” rating and a $ 2.00 target price on the stock. Finally, Zacks Investment Research downgraded Brickell Biotech from a “buy” rating to a “hold” rating in a research report on Tuesday.
Numerous institutional investors and hedge funds have recently increased or decreased their holdings in BBI. Citadel Advisors LLC increased its holdings in Brickell Biotech stock by 111.9% in Q4. Citadel Advisors LLC now owns 168,587 shares in the company worth $ 39,000 after purchasing an additional 89,038 shares in the last quarter. BlackRock Inc. increased its stake in Brickell Biotech by 239.4% during the fourth quarter. BlackRock Inc. now owns 215,682 shares of the company valued at $ 49,000 after acquiring an additional 152,138 shares in the last quarter. Virtu Financial LLC acquired a new stake in Brickell Biotech during Q4 worth approximately $ 51,000. Two Sigma Investments LP increased its stake in Brickell Biotech by 277.2% during Q3. Two Sigma Investments LP now owns 90,085 shares in the company worth $ 65,000 after acquiring another 66,200 shares in the last quarter. Finally, Morgan Stanley increased its stake in Brickell Biotech by 142.0% during Q1. Morgan Stanley now owns 75,404 shares in the company valued at $ 82,000 after acquiring an additional 44,248 shares during the last quarter. 14.99% of the stock is owned by hedge funds and other institutional investors.
About Brickell Biotech (Get evaluation)
Brickell Biotech, Inc, a clinical stage pharmaceutical company, is engaged in the development of various prescription drugs for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironio bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent interferon gene inhibitor stimulator for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.
Get news and ratings for Brickell Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Brickell Biotech and related companies with MarketBeat.com’s FREE daily newsletter.